# GEN2 Directed Cancer Immunotherapy Trial

> **NCT04313868** · PHASE1 · COMPLETED · sponsor: **GenVivo, Inc.** · enrollment: 61 (actual)

## Conditions studied

- Hepatocellular Carcinoma
- Metastatic Cancer

## Interventions

- **DRUG:** GEN2 (HSV-Thymidine Kinase-m2 and hGM-CSF Genes)

## Key facts

- **NCT ID:** NCT04313868
- **Lead sponsor:** GenVivo, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06-13
- **Primary completion:** 2023-12-12
- **Final completion:** 2023-12-12
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2024-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04313868

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04313868, "GEN2 Directed Cancer Immunotherapy Trial". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04313868. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*